Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies.
Wang J, Li C, He K, Kuang Z, Lu J, Yao Y, He F, Li N, Li L, Fu F, Wu Z, Zhou S, Kang D, Qiu X, Wu M, Liu Y, Cao X, Xu M, Chen B, Wu W, Guo F.
Wang J, et al. Among authors: he f, he k.
Cancer Immunol Immunother. 2023 Feb;72(2):493-507. doi: 10.1007/s00262-022-03267-5. Epub 2022 Aug 13.
Cancer Immunol Immunother. 2023.
PMID: 35963895
Free PMC article.